Amgen 2006 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2006 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

The Promise of Our Pipeline
We believe that our pipeline holds the potential to provide more effective treatments for cancer,
osteoporosis, diabetes and other serious illnesses.
Phase 1
Phase 1 clinical trials investigate safety and proper dose ranges
of a product candidate in a small number of human subjects.
Phase 2
Phase 2 clinical trials investigate side effect profiles and efficacy
of a product candidate in a large number of patients who have the
disease or condition under study.
For more information on our pipeline, please visit www.amgen.com. For important safety information about Amgen medicines, please visit www.amgen.com for links to the product websites. This
table is as of January 25, 2007, and shows the status and certain next-expected milestones of selected clinical programs and molecules in Amgen’s product pipeline. Amgen’s product pipeline will
change over time as programs and molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process.
AMG 220
Crohn’s disease
AMG 317
Asthma
AMG 557
Systemic lupus erythematosus
AMG 623
Systemic lupus erythematosus
AMG 714
Psoriasis
AMG 221
Type 2 diabetes
AMG 837
Type 2 diabetes
Sclerostin Ab
Bone loss
AMG 379
Pain
AMG 403
Pain
AMG 386
Cancer
AMG 479
Cancer
AMG 655
Cancer
AMG 745
Muscle wasting disorders
Apo2L/TRAIL
Cancer
AMG 108
Rheumatoid arthritis
Denosumab
Rheumatoid arthritis
Cinacalcet HCI
Primary hyperparathyroidism
AMG 102
Cancer
AMG 531
Chemotherapy-induced thrombocytopenia in non-small
cell lung cancer and lymphoma
AMG 531
Myelodysplastic syndromes
Motesanib diphosphate (formerly identified as AMG 706)
First-line breast cancer
Motesanib diphosphate
First-line non-small cell lung cancer
Motesanib diphosphate
Thyroid cancer
Palifermin
Oral mucositis associated with radiation therapy
and chemotherapy for solid tumors
Panitumumab
Head and neck cancer
Amgen 2006 Annual Report 4